Search results for "PLACEBO"

showing 10 items of 704 documents

Molecular bases of anorexia nervosa, bulimia nervosa and binge eating disorder: shedding light on the darkness

2017

International audience; Eating-disorders (EDs) consequences to human health are devastating, involving social, mental, emotional, physical and life-threatening aspects, concluding on impairment and death in cases of extreme anorexia nervosa. It also implies that people suffering an ED need to find psychiatric and psychological help as soon as possible to achieve a fully physical and emotional recovery. Unfortunately, to date, there is a crucial lack of efficient clinical treatment to these disorders. In this review, we present an overview concerning the actual pharmacological and psychological treatments, the knowledge of cells, circuits, neuropeptides, neuromodulators and hormones in the h…

Anorexia NervosaPsychotherapistcognitive-behavioral therapy[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionneuromodulatorsAnorexia nervosa/bulimia03 medical and health sciencesCellular and Molecular NeuroscienceHuman health0302 clinical medicineplacebo-controlled trialBinge-eating disordermesolimbic dopamine systemGeneticsmedicineHumansGenetic Predisposition to DiseaseBulimia NervosaClinical treatmentregulate feeding-behaviornucleus-accumbens shellborderline personality-disordergene-environment interactionsmedicine.disease030227 psychiatryEating disorderssubstance use disordersAnorexia nervosa (differential diagnoses)genetic approachesrandomized controlled-trialEating disordersgenome-wide associationpharmacologyPsychology[SDV.AEN]Life Sciences [q-bio]/Food and NutritionBinge-Eating Disorder030217 neurology & neurosurgeryClinical psychologyJournal of Neurogenetics
researchProduct

Maladaptive and adaptive emotion regulation through music a behavioral and neuroimaging study of males and females

2015

Music therapists use guided affect regulation in the treatment of mood disorders. However, self-directed uses of music in affect regulation are not fully understood. Some uses of music may have negative effects on mental health, as can non music regulation strategies, such as rumination. Psychological testing and functional magnetic resonance imaging (fMRI) were used explore music listening strategies in relation to mental health. Participants (n = 123) were assessed for depression, anxiety and Neuroticism, and uses of Music in Mood Regulation (MMR). Neural responses to music were measured in the medial prefrontal cortex (mPFC) in a subset of participants (n = 56). Discharge, using music to…

AnxietyPLACEBO-CONTROLLED TRIALBehavioral NeuroscienceDOUBLE-BLINDmielenterveysta515Original Researchprefrontal cortexmedicine.diagnostic_testfMRIHEAVY-METAL MUSICNeuroticismhumanitiesPsychiatry and Mental healthNeuropsychology and Physiological PsychologyNeurologygender differencesDEPRESSIVE SYMPTOMSta6131Anxietymedicine.symptomPsychologymental healthClinical psychologyemotion regulationMusic therapy515 Psychologysukupuolierotmusiikkibehavioral disciplines and activitiesta3112INDIVIDUAL-DIFFERENCESlcsh:RC321-571MOOD REGULATIONmedicinemusicMusic Therapylcsh:Neurosciences. Biological psychiatry. NeuropsychiatryBiological PsychiatryGENDER-DIFFERENCESmedicine.diseaseMental healthMoodSELF-REGULATIONMood disordersPSYCHIATRIC-PATIENTSRuminationINTERFERON-ALPHAFunctional magnetic resonance imaginghuman activitiesNeuroscienceFRONTIERS IN HUMAN NEUROSCIENCE
researchProduct

Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acet…

2010

Pulmonary function is impaired in untreated mucopolysaccharidosis type VI (MPS VI). Pulmonary function was studied in patients during long-term enzyme replacement therapy (ERT) with recombinant human arylsulfatase B (rhASB; rhN-acetylgalactosamine 4-sulfatase). Pulmonary function tests prior to and for up to 240 weeks of weekly infusions of rhASB at 1 mg/kg were completed in 56 patients during Phase 1/2, Phase 2, Phase 3 and Phase 3 Extension trials of rhASB and the Survey Study. Forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1) and, in a subset of patients, maximum voluntary ventilation (MVV), were analyzed as absolute volume in liters. FEV1 and FVC showed little change f…

Arylsulfatase BAdultmedicine.medical_specialtyVital capacityAdolescentMucopolysaccharidoses (MPS)N-Acetylgalactosamine-4-SulfataseMucopolysaccharidosis type VIClinical SciencesUrologyPulmonary function testingPlacebos03 medical and health sciencesFEV1/FVC ratio0302 clinical medicineRare DiseasesDouble-Blind MethodClinical ResearchmedicineGeneticsHumansGenetics(clinical)Longitudinal StudiesChildPreschoolLungGenetics (clinical)Genetics & Heredity0303 health sciencesLungMucopolysaccharidosis VIbusiness.industry030305 genetics & heredityEvaluation of treatments and therapeutic interventionsMucopolysaccharidosis VIEnzyme replacement therapyRecombinant Proteins3. Good healthSurgeryRespiratory Function Testsmedicine.anatomical_structureCross-Sectional StudiesResearch DesignChild Preschool6.1 PharmaceuticalsOriginal Articlebusiness030217 neurology & neurosurgery
researchProduct

MTHFR 677C → T genotype modulates the effect of a 5-year supplementation with B-vitamins on homocysteine concentration: The SU.FOL.OM3 randomized con…

2018

Aims To study how MTHFR 677C→T genotype modulates the effect of supplementation with B-vitamins on total homocysteine (tHcy) and B-vitamin concentrations. Methods 2381 patients with a personal history of cardiovascular disease were randomly assigned to one of four groups: 1) B-vitamins alone (560 μg of 5-methyl-THF, 3 mg of vitamin B6 and 20 μg of vitamin B12), 2) n-3 fatty acids alone (600 mg of EPA and DHA in a 2:1 ratio), 3) B-vitamins and n-3 fatty acids, and 4) placebo. Participants were followed up for 4.7 years. At baseline and annually thereafter, biological parameters were assessed. Multivariate and linear mixed models were fit to study the interaction between B-vitamins and MTHFR …

B VitaminsMaleHomocysteinePhysiologylcsh:Medicine[SDV.GEN] Life Sciences [q-bio]/Genetics030204 cardiovascular system & hematologyBiochemistryGastroenterologychemistry.chemical_compound0302 clinical medicineBlood plasmaGenotypeMedicine and Health Sciences030212 general & internal medicinelcsh:ScienceHomocysteine[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyMultidisciplinarybiologyOrganic CompoundsFatty AcidsPyridoxineVitaminsMiddle AgedLipidsBody Fluids3. Good healthChemistryBloodCardiovascular DiseasesCreatininePhysical SciencesVitamin B ComplexFemaleAnatomyResearch Articlemedicine.medical_specialtyGenotypePlaceboBlood PlasmaCobalamins03 medical and health sciencesFolic AcidDouble-Blind MethodInternal medicine[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular BiologymedicineHumans[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyVitamin B12Methylenetetrahydrofolate Reductase (NADPH2)[SDV.GEN]Life Sciences [q-bio]/GeneticsCreatininePolymorphism Geneticbusiness.industryOrganic Chemistrylcsh:RChemical CompoundsBiology and Life Sciences[SDV.AEN] Life Sciences [q-bio]/Food and NutritionB vitaminschemistry[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieMethylenetetrahydrofolate reductaseDietary Supplementsbiology.protein[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologielcsh:Qbusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionBiomarkers[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyPLoS ONE
researchProduct

Atypical Antipsychotics in the Treatment of Acute Bipolar Depression with Mixed Features: A Systematic Review and Exploratory Meta-Analysis of Placeb…

2016

Evidence supporting the use of second generation antipsychotics (SGAs) in the treatment of acute depression with mixed features (MFs) associated with bipolar disorder (BD) is scarce and equivocal. Therefore, we conducted a systematic review and preliminary meta-analysis investigating SGAs in the treatment of acute BD depression with MFs. Two authors independently searched major electronic databases from 1990 until September 2015 for randomized (placebo-) controlled trials (RCTs) or open-label clinical trials investigating the efficacy of SGAs in the treatment of acute bipolar depression with MFs. A random-effect meta-analysis calculating the standardized mean difference (SMD) between SGA an…

Bipolar DisorderManic-depressive illness--Treatmentmeta-analysilcsh:ChemistryClinical trials0302 clinical medicineManic-depressive illnessAsenapineAntipsychotic drugslcsh:QH301-705.5Spectroscopydiagnostic and statistical manual for mental disorders fifth edition (DSM-5)PsychiatryDepressionBrief ReportGeneral MedicineComputer Science ApplicationsTreatment OutcomeMeta-analysismixed featureHumanmedicine.drugAntipsychotic Agentsmedicine.medical_specialtyAcute bipolar depression; Diagnostic and statistical manual for mental disorders fifth edition (DSM-5); Meta-analysis; Mixed features; Second generation antipsychotic (SGA); Systematic-review; Physical and Theoretical Chemistry; Organic Chemistry; Spectroscopy; Inorganic Chemistry; Catalysis; Molecular BiologyYoung Mania Rating ScalePlaceboCatalysisInorganic Chemistry03 medical and health sciencessystematic-reviewInternal medicinemedicineHumansZiprasidoneBipolar disorderPhysical and Theoretical ChemistryPsychiatryMolecular BiologyLurasidonemixed featuresbusiness.industryOrganic Chemistrysecond generation antipsychotic (SGA)acute bipolar depressionmedicine.disease030227 psychiatrymeta-analysisAntipsychotic Agentlcsh:Biology (General)lcsh:QD1-999QuetiapineControlled Clinical Trials as Topicbusiness030217 neurology & neurosurgeryInternational Journal of Molecular Sciences
researchProduct

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

2015

BACKGROUND: Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagon-like peptide-1 analogue, has been shown to have potential benefit for weight management at a once-daily dose of 3.0 mg, injected subcutaneously. METHODS: We conducted a 56-week, double-blind trial involving 3731 patients who did not have type 2 diabetes and who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 30 or a BMI of at least 27 if they had treated or untreated dyslipidemia or hypertension. We randomly assigned patients in a 2:1 ratio to receive on…

Blood GlucoseCounselingMaleType 2 diabeteslaw.inventionBody Mass IndexRandomized controlled trialWeight losslawGlucagon-Like Peptide 1Weight managementSubcutaneousMedicine (all)ReducingNauseaGeneral MedicineMiddle AgedCombined Modality Therapy3. Good healthFemaletype 2 diabetesmedicine.symptomHumanmedicine.drugAdultDiarrheamedicine.medical_specialtyDiet ReducingInjections SubcutaneousInjections SubcutaneouPlaceboInjectionsDouble-Blind MethodInternal medicineWeight LossmedicineHumansHypoglycemic AgentsObesityExerciseHypoglycemic AgentLiraglutidebusiness.industryLiraglutidemedicine.diseaseWeight LoDietEndocrinologybusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionBody mass index[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyDyslipidemiaAdult; Blood Glucose; Body Mass Index; Combined Modality Therapy; Counseling; Diarrhea; Diet Reducing; Double-Blind Method; Exercise; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Injections Subcutaneous; Liraglutide; Male; Middle Aged; Nausea; Obesity; Weight Loss; Medicine (all)The New England journal of medicine
researchProduct

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-…

2017

Background: \ud Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes.\ud \ud Methods: \ud In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3·0 mg or matched placebo, as an adjunct to a reduced-…

Blood GlucoseMaleEXENATIDEType 2 diabetes030204 cardiovascular system & hematologyBody Mass Indexlaw.inventionPlacebosImpaired glucose toleranceMELLITUS3.0 MG0302 clinical medicineRandomized controlled trialGlucagon-Like Peptide 1lawPREVENTION PROGRAM OUTCOMESPrediabetesPREVENTION PROGRAM OUTCOMES; IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE; CLINICAL-TRIAL; OBESE SUBJECTS; 3.0 MG; REGRESSION; EXENATIDE; MELLITUSSubcutaneousMedicine (all)General MedicineMiddle AgedAdult; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus Type 2; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Injections Subcutaneous; Liraglutide; Male; Middle Aged; Obesity; Placebos; Prediabetic State; Risk Reduction Behavior; Treatment Outcome; Weight Loss3. Good healthTreatment OutcomeFemaleLIFE-STYLEType 2OBESE SUBJECTSmedicine.drugAdultmedicine.medical_specialtyInjections Subcutaneous030209 endocrinology & metabolismPlaceboIncretinsGlucagon-Like Peptide-1 ReceptorInjectionsCLINICAL-TRIALPrediabetic State03 medical and health sciencesIMPAIRED GLUCOSE-TOLERANCEDouble-Blind MethodDiabetes mellitusInternal medicineWeight LossREGRESSIONDiabetes MellitusmedicineHumansHypoglycemic AgentsObesityLiraglutidebusiness.industryBody WeightLiraglutidemedicine.diseaseClinical trialEndocrinologyDiabetes Mellitus Type 2Human medicinebusinessRisk Reduction Behavior[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe Lancet
researchProduct

Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: Results of the randomized, double-blind, placebo-controll…

2009

High-density-lipoproteins-cholesterol (HDL-C) is invertedly related to the incidence of cardiovascular events. Recent studies suggest that HDL-C directly improves endothelial function. Nicotinic acid (niacin) effectively raises serum HDL-C. We therefore hypothesized that treatment with niacin improves endothelial dysfunction in patients with coronary artery disease (CAD). One hundred seven patients with CAD were randomly assigned to double-blinded treatment for 12 weeks with extended-release (ER)-niacin 1000 mg/day (N) or placebo (C), respectively. Flow-mediated dilation (FMD) of the brachial artery, nitroglycerin-mediated endothelium-independent dilation (NMD) and serum lipid concentration…

Blood GlucoseMalemedicine.medical_specialtyBrachial ArteryVasodilator AgentsAdministration OralCoronary Artery DiseasePlaceboNiacinGastroenterologyCoronary artery diseaseNitroglycerinchemistry.chemical_compoundHigh-density lipoproteinDouble-Blind MethodInternal medicinemedicine.arterymedicineHumansProspective StudiesPhosphorylationEndothelial dysfunctionBrachial arteryTriglyceridesAgedUltrasonographyVascular diseasebusiness.industryCholesterol HDLMicrofilament Proteinsnutritional and metabolic diseasesCholesterol LDLMiddle AgedPhosphoproteinsmedicine.diseaseVasodilationB vitaminsTreatment OutcomeEndocrinologychemistryDelayed-Action PreparationsFemalelipids (amino acids peptides and proteins)Endothelium VascularCardiology and Cardiovascular MedicinebusinessCell Adhesion MoleculesBiomarkersNiacinAtherosclerosis
researchProduct

Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial.

2021

Digital

Blood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismRecombinant Fusion ProteinsGlucagon-Like Peptides030209 endocrinology & metabolismType 2 diabetesPlacebolaw.invention03 medical and health sciences0302 clinical medicineEndocrinologyRandomized controlled trialDouble-Blind MethodErectile DysfunctionlawInternal medicineDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic Agents030212 general & internal medicineRisk factorAgedbusiness.industryIncidence (epidemiology)Middle Agedmedicine.diseasePrognosisImmunoglobulin Fc FragmentsErectile dysfunctionDiabetes Mellitus Type 2Cardiovascular DiseasesDulaglutideFemalebusinessBiomarkersmedicine.drugFollow-Up StudiesThe lancet. Diabetesendocrinology
researchProduct

Oral Magnesium Supplementation for Treating Glucose Metabolism Parameters in People with or at Risk of Diabetes: A Systematic Review and Meta-Analysi…

2021

There is a large and growing body of literature focusing on the use of oral magnesium (Mg) supplementation for improving glucose metabolism in people with or at risk of diabetes. We therefore aimed to investigate the effect of oral Mg supplementation on glucose and insulin-sensitivity parameters in participants with diabetes or at high risk of diabetes, compared with a placebo. Several databases were searched investigating the effect of oral Mg supplementation vs placebo in patients with diabetes or conditions at high risk of diabetes. Data were reported as standardized mean differences (SMDs) with their 95% confidence intervals (CIs) using follow-up data of glucose and insulin-sensitivity …

Blood Glucosemedicine.medical_specialtyMagnesium supplementationCarbohydrate metabolismmagnesiumPlaceboGastroenterologyArticlelaw.inventionDouble blindRandomized controlled trialDouble-Blind MethodlawDiabetes mellitusInternal medicinemedicineDiabetes MellitusHumansTX341-641glucoseRandomized Controlled Trials as TopicNutrition and Dieteticsdiabetesbusiness.industryNutrition. Foods and food supplyGlucose Tolerance Testmedicine.diseaseConfidence intervalmeta-analysisTreatment OutcomediabeteMeta-analysisDietary SupplementsInsulin ResistancebusinessFood ScienceNutrients
researchProduct